European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
: Includes prolonged-release and pulsatile-release tablets designed to alter the rate or timing of drug delivery.
Designed to resist gastric fluid for 2–3 hours but disintegrate in intestinal fluid within 60 minutes.
This article provides a detailed examination of the Tablets monograph, exploring its scope, key requirements, and critical updates, as well as its vital role in the global pharmaceutical regulatory framework.
In the pharmaceutical world, consistency is everything. For solid oral dosage forms, the is the foundational document that defines what a "tablet" actually is and the rigorous tests it must pass to ensure patient safety and efficacy. What Defines a Tablet under 0478? European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
Title: The Quiet Standard
The European Pharmacopoeia (Ph. Eur.) is a publication that sets standards for the quality, purity, and strength of medicines in Europe. The monograph for Tablets (0478) provides a comprehensive set of specifications for the testing and evaluation of tablets, which are a widely used dosage form for administering medicinal products.
This monograph does not apply to lozenges, oral pastes, or oral gums, which are covered under other sections like Oromucosal Preparations (1807) . Primary Tablet Categories In the pharmaceutical world, consistency is everything
Tablets are solid preparations containing a single dose of one or more active substances, typically obtained by compression.
Monograph 0478 begins by establishing a clear, foundational understanding of what a tablet is and, just as importantly, what it is not.
Looking ahead, the Ph. Eur. has transitioned to a fully digital format with its , which is now available online-only on a redesigned platform. This move towards a digital future enhances accessibility and ensures users have the most up-to-date standards at their fingertips. Title: The Quiet Standard The European Pharmacopoeia (Ph
Its specific requirements for tablet categories, mechanical strength, and, most notably, the precise and challenging subdivision rules for scored tablets, ensure patient safety. Through ongoing revisions and international harmonization efforts, monograph 0478 continues to set the gold standard for tablet quality, promoting public health and facilitating the global availability of safe, effective medicines. For any professional involved in pharmaceutical development, manufacturing, or quality assurance, a thorough understanding of this monograph is not optional—it is essential.
Disintegration measures the time required for a tablet to break apart into smaller particles under specific mechanical agitation in a fluid medium. Monograph 0478 establishes clear maximum disintegration time limits based on tablet type: Typically within 15 minutes in water.
The document read like a recipe and a contract. Definitions, nomenclature, identity tests, uniformity, dissolution — each heading framed a patient’s expectation. The monograph did not dictate production methods; instead it set measurable thresholds and validated analytical procedures. Complying with it meant a tablet that would behave as intended from factory line to bedside.
Dissolution testing evaluates the rate at which the API is released from the tablet matrix into a liquid medium, simulating human physiological conditions. This is a critical surrogate marker for in vivo drug absorption and bioavailability. Modified-release and gastro-resistant tablets require highly specialized dissolution profiles (e.g., testing in acid medium followed by a buffer change). C. Disintegration (2.9.1)
